Search results
Results from the WOW.Com Content Network
Health and wellness platform Hims & Hers Health, Inc. (NYSE:HIMS), which has gained traction for its obesity-related portfolio, has highlighted the ongoing difficulties Americans face in accessing ...
Here are the three arguments against Hims & Hers Health I've seen the most: 1. There is a realistic chance the FDA will block companies like Hims & Hers from selling compounded GLP-1 agonists.
Data source: Hims & Hers. For the fourth quarter, Hims & Hers guided for revenue to come in between $465 million and $470 million, representing growth of 89% to 91% from the $246.6 million it ...
U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular weight-loss drug Wegovy to patients in certain professions for $99 a month.
Travis Hoium has positions in Hims & Hers Health. The Motley Fool has positions in and recommends Amazon and Walmart. The Motley Fool has a disclosure policy. Travis Hoium is an affiliate of The ...
The rise of Hims & Hers Health. Founded in 2017, Hims & Hers originally specialized in selling over-the-counter medications and personal care products through its online platform as well as brick ...
In October 2020, Hims closed a deal with Oaktree Capital Management to go public through a blank check company, reaching a valuation of $1.6 billion. [7] As part of the deal, the company was renamed Hims & Hers Health Inc. [11] The transaction was completed in January 2021, and the company started trading publicly on the New York Stock Exchange.
The news was seen as a competitive threat to Hims & Hers, and a number of other pharmacies, and shares of Hims & Hers fell 9.2% on Tuesday and lost 12% for the week as of Thursday's close.